FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/10/096502 [Registered on: 27/10/2025] Trial Registered Prospectively
Last Modified On: 05/03/2026
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Nutraceutical 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   To study the effect of Bioavailable Turmeric Extract on Healthy Aging 
Scientific Title of Study   A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Bioavailable Turmeric Extract on Biological Aging in Healthy Adults 
Trial Acronym  Nil 
Secondary IDs if Any  
Secondary ID  Identifier 
AN-02BCM0825H1-SYN08 version 01 dated 09 Sep 2025  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Binu T Kuruvilla 
Designation  Chief Innovation Officer  
Affiliation  Arjuna Natural Private Limited 
Address  Arjuna Innovation Centre, Clinical Trial Department, Door No. 187/D, Behind ISRO, Erumathala P.O.

Ernakulam
KERALA
683112
India 
Phone  09447818432  
Fax    
Email  drbinu@arjunanatural.com  
 
Details of Contact Person
Scientific Query  
Name  Dr Binu T Kuruvilla 
Designation  Chief Innovation Officer  
Affiliation  Arjuna Natural Private Limited 
Address  Arjuna Innovation Centre, Clinical Trial Department, Door No. 187/D, Behind ISRO, Erumathala P.O.

Ernakulam
KERALA
683112
India 
Phone  09447818432  
Fax    
Email  drbinu@arjunanatural.com  
 
Details of Contact Person
Public Query  
Name  Dr Giby Abraham 
Designation  Senior Scientist Clinical Research 
Affiliation  Arjuna Natural Pvt Ltd 
Address  Arjuna Innovation Centre, Clinical Trial Department, Door No. 187/D, Behind ISRO, Erumathala P.O.

Ernakulam
KERALA
683112
India 
Phone  09995215790  
Fax    
Email  giby.a@arjunanatural.com  
 
Source of Monetary or Material Support  
Arjuna Natural Pvt. Ltd. Desom Road, Aluva - 683102 
 
Primary Sponsor  
Name  Arjuna Natural Pvt Ltd 
Address  Arjuna Innovation Centre, Clinical Trial Department, Door No. 187/D, Behind ISRO, Erumathala P.O., Ernakulam, Kerala. Pin - 683112 
Type of Sponsor  Other [Neutraceutical Company] 
 
Details of Secondary Sponsor  
Name  Address 
Nil  Nil 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Giriraja K V  Rajalakshmi Hospital and Research Center  Room No.1, General Medicine OPD, Ground Floor, No.21/1, Lakshmipura Main Road, Opp. Lakshmipura Lake, Vidyaranyapura Post
Bangalore
KARNATAKA 		 09448039952

drgiriraja@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Rajalakshmi Hospital Institutional Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Healthy Human Volunteers  Healthy Adults 
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Bioavailable Turmeric extract  One capsule in the morning containing 100 mg of Turmeric extract complex for 60 days 
Intervention  Bioavailable Turmeric extract  One capsule in the morning containing 200 mg of Turmeric extract complex for 60 days 
Comparator Agent  Placebo  One capsule in the morning for 60 days 
 
Inclusion Criteria  
Age From  50.00 Year(s)
Age To  70.00 Year(s)
Gender  Both 
Details  1. Males or female participants aged 50 years to 70 years
2. No clinically diagnosed chronic diseases
3. Normal blood pressure (SBP less than than 140 mmHg, DBP less than 90 mmHg)
4. Normal fasting blood glucose (less than or equal to 100 mg/dL)
5. Normal lipid profile (Total cholesterol less than 200 mg/dL, LDL less than 150 mg/dL, HDL greater than 40 mg/dL,
Triglycerides less than 150 mg/dL)
6. BMI 18.5 – 29.9 kg/m²
7. Willingness to provide informed consent and comply with study procedures 
 
ExclusionCriteria 
Details  1. Clinically diagnosed conditions (hypertension, diabetes, cardiovascular disease, metabolic disorders)
2. Use of anti-inflammatory, antioxidant, or immune-modulating medications/supplements within 30 days before study enrolment
3. Major surgery or hospitalization in the past six months
4. Participation in another clinical trial within three months
5. Smoking or excessive alcohol consumption (greater than 2 standard drinks/day)
6. Any condition that may interfere with study compliance or data interpretation. 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Pre-numbered or coded identical Containers 
Blinding/Masking   Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded 
Primary Outcome  
Outcome  TimePoints 
Mean change in inflammatory and oxidative stress biomarkers  Baseline, Day 30, Day 60 
 
Secondary Outcome  
Outcome  TimePoints 
Mean change in other metabolic and age-related biomarkers  Baseline, Day 30, Day 60 
Mean change in scores of the assessment questionnaires  Baseline, Day 30, Day 60 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2 
Date of First Enrollment (India)   27/10/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  		 Closed to Recruitment of Participants 
Recruitment Status of Trial (India)  Closed to Recruitment of Participants 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   We hypothesize that supplementation with bioavailable curcumin will improve markers of healthy ageing by reducing oxidative stress and systemic inflammation, supporting cognitive and physical performance,  and promoting overall physiological resilience in healthy adults.  The study will assess parameters that are mechanistically linked to ageing, including: Inflammatory markers to evaluate curcumin’s anti-inflammatory effect, Oxidative stress biomarkers to determine antioxidant capacity, Cognitive and physical function assessments to measure real-world implications of healthy ageing and Quality of life scores to assess subjective wellbeing. These parameters will help us comprehensively explore the healthy ageing potential of curcumin and provide translational evidence to support its use as a safe, nutraceutical intervention for longevity and improved life quality.
 
Close